Catalyst calendar
Biotech catalysts in October 2026
13 catalysts are dated to October 2026, including 2 FDA decisions. The first with a set day is Phase 1/2a interim results for VMT-NET (Perspective Therapeutics) on Oct 23. Events placed only in a quarter or half-year are on the 90-day calendar.
Firm dates · a specific day set by the company or regulator
Next 30 days
- Oct 23in 10 daysVMT-NET · Phase 1/2a interim results · SSTR2-positive neuroendocrine tumors
- Oct 23in 10 daysAzer-cel · Phase 1 enrollment complete · Progressive multiple sclerosis
- Oct 24in 11 daysEVX-01 · Phase 2 long-term results · Advanced melanoma
- Oct 26in 13 daysBepirovirsen · FDA decision · Chronic hepatitis B
- Oct 31in 18 daysBHV-1530 · Phase 1 interim results · Advanced solid tumors · FGFR3-altered or overexpressing
Estimated timing · a month, quarter, half-year or year-end the company gave
Expected in October 2026
- October 2026Lifileucel · Phase 2 updated results (IOV-COM-202) · Advanced melanoma · frontline
- October 2026Phentolamine Ophthalmic Solution · Phase 3 topline results (LYNX-3) · Visual disturbances · post-keratorefractive surgery · mesopic, low-contrast conditions
- October 2026
- October 2026ORIC-114 · Results · NSCLC · EGFR exon 20 / EGFR atypical
- October 2026SL-325 · IND submission · Hidradenitis suppurativa · moderate to severe
- October 2026Foralumab · Phase 2a results (INFORM-MS) · Multiple sclerosis · non-active secondary progressive
- October 2026ENTR-601-45 · Phase 1/2 results (ELEVATE-45-201) · Duchenne muscular dystrophy · exon 45 skipping amenable
- October 2026VS-7375 · Results · Advanced KRAS G12D-mutant solid tumors